Feasibility and efficacy of 223Ra-dichloride in treatment of bone metastases in patients with castration-refractory prostate cancer (mCRPC)

被引：0
|
作者：
Mazzarri, S. [1 ]
Boni, G. [1 ]
Borso, E. [2 ]
Galli, L. [3 ]
Farnesi, A. [3 ]
Betti, F. [1 ]
Antonacci, L. [1 ]
Traino, A. [4 ]
Ricci, S. [3 ]
Volterrani, D. [1 ]
机构：
[1] Univ Hosp Pisa, Reg Ctr Nucl Med, Pisa, Italy
[2] SantAndrea Hosp La Spezia, Div Nucl Med, La Spezia, Italy
[3] Univ Hosp Pisa, Div Oncol, Pisa, Italy
[4] Univ Hosp, Sect Med Phys, Hlth Phys Unit, Pisa, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2015年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP136
引用
收藏
页码：S57 / S58
页数：2
相关论文
共 50 条
  • [31] Dosimetry-Based Consideration on Remission and Relapse after Therapy with 223Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
    Mangano, Anna Maria
    Pacilio, Massimiliano
    Ialongo, Pasquale
    Semprebene, Alessandro
    Ventroni, Guido
    Mango, Lucio
    DIAGNOSTICS, 2018, 8 (01):
  • [32] Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride
    Massimiliano Pacilio
    Guido Ventroni
    Giuseppe De Vincentis
    Bartolomeo Cassano
    Rosanna Pellegrini
    Elisabetta Di Castro
    Viviana Frantellizzi
    Giulia Anna Follacchio
    Tatiana Garkavaya
    Leda Lorenzon
    Pasquale Ialongo
    Roberto Pani
    Lucio Mango
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 21 - 33
  • [33] The efficacy of Ra-223-dichloride treatment for bone-metastatic lesions in patients with castration-resistant prostatic cancer
    Kuji, Ichiei
    Yamane, Tomohiko
    Fukushima, Kenji
    Seto, Akira
    Koshiro, Nishimoto
    Kaneko, Tsuyoshi
    Shirotake, Suguru
    Oyama, Masafumi
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [34] Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride
    Pacilio, Massimiliano
    Ventroni, Guido
    De Vincentis, Giuseppe
    Cassano, Bartolomeo
    Pellegrini, Rosanna
    Di Castro, Elisabetta
    Frantellizzi, Viviana
    Follacchio, Giulia Anna
    Garkavaya, Tatiana
    Lorenzon, Leda
    Ialongo, Pasquale
    Pani, Roberto
    Mango, Lucio
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (01) : 21 - 33
  • [35] Radium-223 Dichloride: A Novel Treatment Option for Castration-Resistant Prostate Cancer Patients With Symptomatic Bone Metastases
    McGann, Shane
    Horton, Evan R.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (04) : 469 - 476
  • [36] RADIUM RA 223 DICHLORIDE IN CASTRATION-RESISTANT PROSTATE CANCER
    Joung, J. Y.
    Ha, Y-S.
    Kim, I. Y.
    DRUGS OF TODAY, 2013, 49 (08) : 483 - 490
  • [37] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, G.
    Fang, F.
    Vogelzang, N. J.
    ONKOLOGIE, 2013, 36 : 78 - 78
  • [38] Hematologic safety of Ra-223 dichloride (Ra-223) in castration- resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Fang, F.
    Vogelzang, N. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 60
  • [39] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial
    Parker, Chris
    Garcia-Vargas, Jose E.
    O'Bryan-Tear, C. Gillies
    Fang, Fang
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Hematotoxicity and non-hematological adverse events of Ra-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases.
    Ahmadzadehfar, Hojjat
    Azgomi, Kambiz
    Rogenhofer, Sebastian
    Bundschuh, Ralph
    Kuerpig, Stefan
    Essler, Markus
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
12345